L Liu1, M Han2, R Qie2, Q Li2, X Zhang1,3, J Zhang1,4, S Zhan1,5, L Zhang1, Z Xu1, C Zhang1, F Hong6. 1. School of Public Health, the Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Dongqing Road, Guian New Area, Guiyang, 550025, Guizhou, People's Republic of China. 2. College of Public Health, Zhengzhou University, Zhengzhou, 450000, People's Republic of China. 3. Center for Diseases Control and Prevention of Yunyan District, Guiyang, 550004, People's Republic of China. 4. Guiyang Center for Diseases Control and Prevention, Guiyang, 550001, People's Republic of China. 5. Guizhou Provincial Hospital of Maternal and Child Health Care, Guiyang, 550004, People's Republic of China. 6. School of Public Health, the Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Dongqing Road, Guian New Area, Guiyang, 550025, Guizhou, People's Republic of China. fhong@gmc.edu.cn.
Abstract
PURPOSE: Previous studies have not fully described the relationship between high-density lipoprotein cholesterol (HDL-C) and death risks from all cause and cardiovascular disease (CVD). This study quantitatively evaluates HDL-C-mortality associations. METHODS: Embase and PubMed databases were searched for relevant articles published up to 1 June 2019. Random-effects models were used to pool relative risks (RRs) and 95% confidence intervals (CIs). We used restricted cubic splines to model the dose-response association. RESULTS: We identified 32 prospective cohort studies including 369,904 participants and 33,473 total deaths (9426 CVD deaths). Compared to the lowest HDL-C levels, all cause and CVD mortality risks were reduced by 18% (RR 0.82; 95% CI, 0.73-0.93) and 36% (0.64, 0.46-0.89), respectively, for the highest HDL-C levels. All cause and CVD mortality risks were reduced by 15% (0.85, 0.79-0.92) and 23% (0.77, 0.69-0.87), respectively, with each 1 mmol/L increment of HDL-C. We found evidence of nonlinear and negative dose-response associations of HDL-C with all cause and CVD mortality (Pnonlinearity < 0.001), and the lowest death risks from all cause and CVD were observed at approximately 1.34 and 1.55 mmol/L, respectively. CONCLUSION: HDL-C is inversely associated with all cause and CVD mortality risks under approximately 2.05 and 2.33 mmol/L, respectively. Optimal doses require investigation via clinical practice or high-quality research.
PURPOSE: Previous studies have not fully described the relationship between high-density lipoprotein cholesterol (HDL-C) and death risks from all cause and cardiovascular disease (CVD). This study quantitatively evaluates HDL-C-mortality associations. METHODS: Embase and PubMed databases were searched for relevant articles published up to 1 June 2019. Random-effects models were used to pool relative risks (RRs) and 95% confidence intervals (CIs). We used restricted cubic splines to model the dose-response association. RESULTS: We identified 32 prospective cohort studies including 369,904 participants and 33,473 total deaths (9426 CVD deaths). Compared to the lowest HDL-C levels, all cause and CVD mortality risks were reduced by 18% (RR 0.82; 95% CI, 0.73-0.93) and 36% (0.64, 0.46-0.89), respectively, for the highest HDL-C levels. All cause and CVD mortality risks were reduced by 15% (0.85, 0.79-0.92) and 23% (0.77, 0.69-0.87), respectively, with each 1 mmol/L increment of HDL-C. We found evidence of nonlinear and negative dose-response associations of HDL-C with all cause and CVD mortality (Pnonlinearity < 0.001), and the lowest death risks from all cause and CVD were observed at approximately 1.34 and 1.55 mmol/L, respectively. CONCLUSION: HDL-C is inversely associated with all cause and CVD mortality risks under approximately 2.05 and 2.33 mmol/L, respectively. Optimal doses require investigation via clinical practice or high-quality research.
Authors: Niku Oksala; Ilkka Seppälä; Jussi Hernesniemi; Leo-Pekka Lyytikäinen; Mika Kähönen; Kari-Matti Mäkelä; Antti Reunanen; Antti Jula; Mika Ala-Korpela; Terho Lehtimäki Journal: Ann Med Date: 2012-04-24 Impact factor: 4.709
Authors: Bruce M Psaty; Melissa Anderson; Richard A Kronmal; Russell P Tracy; Trevor Orchard; Linda P Fried; Thomas Lumley; John Robbins; Greg Burke; Anne B Newman; Curt D Furberg Journal: J Am Geriatr Soc Date: 2004-10 Impact factor: 5.562
Authors: Robert W McGarrah; Damian M Craig; Carol Haynes; Z Elaine Dowdy; Svati H Shah; William E Kraus Journal: Atherosclerosis Date: 2016-01-11 Impact factor: 5.162